series-a
Stage
1
Investors
About
Develops hyperspectral retinal scan technology to detect Alzheimer’s disease years before symptoms appear by analysing retinal biomarkers. Provides diagnostic imaging solutions aimed at early, non‑invasive detection of neurodegenerative disease.
Explore RetiSpec's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.